Medical AI Alliance
← Company Index
Medical AIKOSDAQ 2263302 approvals

SyntekaBio,Inc.

Official website

Founded in 2009, SyntekaBio provides genomic big data-based AI drug discovery platforms DeepMatcher and NEO-ARS, along with the NGS-ARS precision medicine service.

As of 2026-10-10, SyntekaBio,Inc. has 2 Korean MFDS device approvals, 20 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2009 and listed on KOSDAQ in 2019, SyntekaBio is an AI drug discovery company built on genomic big data. It offers the AI drug discovery platform DeepMatcher (hit screening and lead optimization), NEO-ARS (neoantigen discovery), AB-ARS (antibody prediction and optimization), and the genomic precision medicine service NGS-ARS. NGS-ARS generates revenue through services provided to domestic university hospitals, and the company is developing its own drug pipeline (synthetic drugs, drug repositioning, neoantigen and antibody therapeutics) alongside a newly launched SI service that builds digital platforms for biotech companies.

Products & technology

  • DeepMatcherHit screening and lead optimization service
  • NEO-ARSPersonalized neoantigen discovery and screening service
  • AB-ARSNovel antibody prediction and optimization service
  • NGS-ARSGenomic precision medicine service, generating revenue from domestic university hospitals
  • SI ServiceDigital platform (website/IR content) construction service for biotech companies

Regulatory approvals

data.go.kr

2 Korean MFDS device approvals · 2020

  • MFDSIVD reagents for extracting nucleic acids2020-03-20
    Product approval · Class 1체외 제신 20-377 호
  • MFDSIVD reagents for extracting nucleic acids2020-02-10
    Product approval · Class 1체외 제신 20-168 호

R&D and key agreements

Source: DART corporate disclosure

자체 신약파이프라인 · Synthetic drug, drug repositioning, and cancer vaccine/cell therapy target discovery using DeepMatcher and NEO-ARS

Key disclosures

KRX KIND via OpenDART
Show 21 more events

Publications

PubMed · affiliation-matched
Show 10 more publications

Patents

KIPRIS · applicant-matched
Show 84 more patents

AI reads

MAA server logs · IP-verified
31
Times AI engines pulled SyntekaBio,Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

30
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

6
live 1
Last 7 days
20
live 1
Last 30 days
31
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot17
  • GoogleGoogleOther7
  • PerplexityPerplexityBot3
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 7, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for SyntekaBio,Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsMedical AI

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Gencurix Inc.1 shared

Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.

GENOLUTION INC.1 shared

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

OSANG HEALTHCARE CO.,LTD.1 shared

Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.

Median Diagnostics Inc.1 shared

Founded in 1999 and listed on KONEX in 2017, Median Diagnostics develops and manufactures immunoassay, molecular, and point-of-care in vitro diagnostic kits for animal diseases.

Precision Biosensor Inc.1 shared

KOSDAQ-listed IVD company producing time-resolved fluorescence immunodiagnostic products under the Exdia TRF brand.

PCL. Inc1 shared

KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.

Optipharm.CO.,LTD1 shared

Optipharm, founded in 2000 and KOSDAQ-listed in 2018, provides animal disease diagnostics, animal medicine, and biotech.

GC Medical Science Corporation1 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

SEEGENE, INC.1 shared

Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.

CALTH. Inc1 shared

Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.

Genesystem Co., Ltd1 shared

Founded 2010, listed on KOSDAQ in 2021, Genesystem develops molecular diagnostic systems, biochips, test kits, and reaction reagents.

SD BIOSENSOR INC.1 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition